$CIPLA Cipla Ltd (CIPLA) news update – 22 June 2026

💊 Market Snapshot 📈 CMP: ₹1,419 🚀 Up 4.69% 🏥 Sector: Pharmaceuticals 🔥 Rally driven by new USFDA approval and strong export outlook 📰 Key Highlights USFDA Approval Boost Cipla received USFDA clearance for its generic asthma inhaler (Advair Diskus equivalent). Expected to add significant revenue from FY27 onward in the US market. Digital Health Expansion Launched “CiplaRespire”, a smart respiratory monitoring device integrated with mobile app support. Strengthens Cipla’s leadership in chronic respiratory care. Financial Performance (Q4 FY26) Revenue: ₹6,210 Cr (+11% YoY) Net Profit: ₹950 Cr (+14% YoY) Margin expansion driven by North America and chronic therapies. Strategic Outlook Expanding biosimilar portfolio in oncology and immunology. Focus on AI-driven drug discovery and digital health platforms. Analyst View Brokerages revise target to ₹1,480–₹1,520. Positive sentiment on export growth and respiratory segment leadership. 📊 Investor Takeaways Short-term catalyst: USFDA approval and digital health launch. Long-term drivers: Biosimilars, AI drug discovery, and export expansion. Support: ₹1,380 | Resistance: ₹1,450